# C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

> **NCT03635632** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 94 (estimated)

## Conditions studied

- Relapsed Neuroblastoma
- Refractory Neuroblastoma
- Relapsed Osteosarcoma
- Relapsed Ewing Sarcoma
- Relapsed Rhabdomyosarcoma
- Uveal Melanoma
- Phyllodes Breast Tumor

## Interventions

- **GENETIC:** C7R-GD2.CART cells

## Key facts

- **NCT ID:** NCT03635632
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-23
- **Primary completion:** 2023-05-16
- **Final completion:** 2038-05-16
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03635632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03635632, "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03635632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*